DexCom, Inc. (DXCM)

134,30 +0,44 (+0,33 %) À la clôture : 04:00PM EDT

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 9 500

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Kevin Ronald Sayer	Executive Chairman, CEO & President	2,22M	S.O.	1958
Mr. Jereme M. Sylvain	Executive VP, CFO & Chief Accounting Officer	841,14k	S.O.	1980
Mr. Jacob Steven Leach	Executive VP & COO	994,13k	S.O.	1978
Mr. Girish Naganathan	Executive VP & CTO	423,92k	S.O.	1977
Mr. Michael Jon Brown	Executive VP & Chief Legal Officer	954,46k	S.O.	1970
Mr. Shelly Ramasamy Selvaraj	Senior VP & Chief Information Officer	S.O.	S.O.	1959
Mr. Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	S.O.	S.O.	S.O.
Mr. Matthew Dolan	Executive Vice President of Strategy, Corporate Development & Dexcom Labs	S.O.	S.O.	1981
Ms. Leverne Marsh	Executive Vice President of Marketing	S.O.	S.O.	S.O.
Ms. Sadie M. Stern	Executive VP & Chief Human Resources Officer	S.O.	S.O.	1975

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de DexCom, Inc. en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 2; Société : 9; Droits des actionnaires : 6; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.